Skip to main content

Table 1 Selected ongoing clinical trials investigating immunotherapy based therapies targeting pancreatic cancer microenvironment

From: Pancreatic cancer microenvironment: a current dilemma

Identifier

Trial design/phase/current status

Rationale

Study group

NCT02243371

GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 with or without nivolumab/phase2/active, not recruiting

Priming of tumor microenvironment and T cells/activation of effector immune system

Previously treated metastatic pancreatic adenocarcinoma

NCT03153410

Pilot study of cyclophosphamide, pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in patients with borderline resectable adenocarcinoma of the pancreas/phase 1/recruiting

Depleting/inhibiting negative regulators of immune response and priming of tumor microenvironment

Borderline resectable adenocarcinoma

NCT03190265

Study of CRS-207, nivolumab and ipilimumab with or without GVAX pancreas vaccine (with CY) in patients with pancreatic cancer/recruiting

Priming of tumor microenvironment and T cells/activation of effector immune system

Previously treated metastatic pancreatic adenocarcinoma

NCT03161379

GVAS pancreas vaccine with cyclophosphamide in combination with nivolumab and SBRT for patients with borderline resectable pancreatic cancer/phase 2/recruiting

Priming of tumor microenvironment and T cells/activation of effector immune system

Borderline resectable pancreatic adenocarcinoma

NCT02451982

Neoadjuvant/adjuvant GVAX pancreas vaccine (with CY) With or without nivolumab and urelumab trial for surgically resectable pancreatic cancer/phase1-2/recruiting

Priming of tumor microenvironment and activation of effector immune cells

Surgically resectable pancreatic adenocarcinoma

NCT02648282

Study with cyclophosphamide pembrolizumab, GVAX, and SBRT in patients with locally advanced pancreatic cancer/phase2/recruiting

Priming of tumor microenvironment and activation of effector immune cells

Locally advance pancreatic adenocarcinoma